Press Release August 14, 2021FDA Approves Merck's Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors 0 0 Share
Company Ticker News August 12, 2021Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer 0 0 Share
Press Release August 12, 2021FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC) 0 0 Share
Company Ticker News August 11, 2021Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA 0 0 Share
Press Release August 10, 2021FDA Grants Priority Review to Merck's Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery 0 0 Share
Press Release August 10, 2021FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma 0 0 Share
Company Ticker News August 8, 2021MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q2 2021 Results - Earnings Call Transcript 0 0 Share
Company Ticker News August 1, 2021Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market? 0 0 Share
Company Ticker News July 29, 2021Merck Sales Beat Estimates, But the Stock Fell. Here's 1 Reason to Be Bullish. 0 0 Share
Press Release July 27, 2021Merck's Keytruda Combo Trial Meets Overall Survival Endpoint In PD-L1 Expressing Breast Cancer Patients 0 0 Share
